

EudraCT Team
European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

27th August 2021

Re. EudraCT number: 2014-001571-31

Title: A randomized (open-label design) parallel group, multicentre study to evaluate the safety and tolerability of two different doses of Depigoid 34% Grasses Mix, 33% *Olea europaea* and 33% *Salsola kali* 3000 DPP/ml in subjects with allergic rhinitis and rhinoconjunctivitis, with or without controlled asthma.

Dear EudraCT team,

According to your request about the referenced trial result post. We confirm that the clinical trial was prematurely ended; no subjects were recruited for this trial. Clinical investigators and Ethics Committees were informed accordingly.

Do not hesitate to come back to us for further information.

Yours sincerely,

Alicia Marín de Pablo
Clinical Operations Manager,
LETI Pharma S.L.U.
amarin@leti.com